The National Cancer Institute is offering a limited competition grant to the current awardee of the Adult Brain Tumor Consortium (ABTC) for the development of new anticancer therapies for adult patients with brain tumors, focusing on glioblastoma multiforme (GBM). The program requires the Consortium to conduct clinical research on the early-stage development of new agents for GBM treatment, with an emphasis on translational research to understand the biological and molecular factors improving the response of GBM to new agents. Comprehensive evaluations including pharmacokinetic and pharmacodynamic assessments are essential. Closing date for applications is September 16, 2013.
Opportunity ID: 236596
General Information
| Document Type:: | Grants Notice |
| Funding Opportunity Number:: | RFA-CA-13-501 |
| Funding Opportunity Title:: | Limited Competition: Adult Brain Tumor Consortium (ABTC) (UM1) |
| Opportunity Category:: | Discretionary |
| Opportunity Category Explanation:: | |
| Funding Instrument Type:: | |
| Category of Funding Activity:: | Education |
| Category Explanation:: | |
| Expected Number of Awards:: | 1 |
| Assistance Listings Number(s):: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement:: | No |
| Version:: | Synopsis 2 |
| Posted Date:: | Jun 19, 2013 |
| Last Updated Date:: | Jun 19, 2013 |
| Original Closing Date for Applications:: | Sep 16, 2013 |
| Current Closing Date for Applications:: | Sep 16, 2013 |
| Archive Date:: | Oct 17, 2013 |
| Estimated Total Program Funding:: | $ 2,000,000 |
| Award Ceiling:: | $2,000,000 |
| Award Floor:: | $ |
Eligibility
| Eligible Applicants:: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility:: | Other Eligible Applicants include the following: Only the current awardees of Adult Brain Tumor Consortium funded under RFA-CA-08-504 are eligible to apply. Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. |
Additional Information
| Agency Name:: | National Institutes of Health |
| Description:: | The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue the program of the National Cancer Institute (NCI) for the development of new anticancer therapies for adult patients with brain tumors, especially glioblastoma multiforme (GBM). This limited competition FOA solicits a single application from the current awardee of the Adult Brain Tumor Consortium (ABTC). The ABTC is a NCI-funded clinical trials group that performs clinical research on the treatment of patients with GBM. In this funding period, the ABTC is expected to remain focused on the early stage development of new agents for treatment of GBM. However, in addition to identifying agents with antitumor activity in patients participating in Phase I and II clinical trials, the Consortium will be expected to expand and enrich its translational research. These aspects include increased emphasis on the identification of the effects of anticancer agents on their intended targets and other studies to increase understanding of biological and molecular factors that may improve the response of GBM to new agents. ABTC must be capable of conducting comprehensive pharmacokinetic and pharmacodynamic evaluations, characterization of drug effects on relevant cellular targets (using appropriate biospecimens) and integrating such findings. |
| Link to Additional Information:: | |
| Grantor Contact Information:: | If you have difficulty accessing the full announcement electronically, please contact: |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Synopsis 2 | Modified Eligibility list | Jun 19, 2013 |
| Synopsis 1 |
Package Status
Package No: 1